Schizophrenia - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Schizophrenia Market Outlook

Thelansis's "Schizophrenia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Schizophrenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Schizophrenia Overview

Schizophrenia is a chronic, disabling psychiatric disorder characterized by positive symptoms (hallucinations, delusions, disorganized speech) and negative symptoms (social withdrawal, avolition, blunted affect). Its multifactorial etiology involves genetic vulnerability, environmental stressors, and dysregulation of dopamine, glutamate, and acetylcholine pathways. Diagnosis relies on clinical psychiatric assessment using DSM-5-TR or ICD-11 criteria, both of which emphasize dimensional symptom severity rather than historical, rigid clinical subtypes. Management requires lifelong, multidisciplinary care combining psychosocial interventions with advanced pharmacotherapy. While traditional antipsychotics rely on dopamine D2 receptor antagonism, the modern therapeutic paradigm preferentially deploys next-generation oral muscarinic receptor agonists (such as xanomeline-trospium) to effectively modulate circuits and alleviate symptoms without causing extrapyramidal or metabolic side effects, utilizing acute hospitalization to ensure safety during severe exacerbations.

Key Highlights

• In the United States, diagnosis rates are high, with ~95% of cases identified, reflecting strong clinical awareness and screening.
• Approximately 77% of patients receive drug treatment (2025), indicating a notable gap between diagnosis and treatment uptake.
• Persistent unmet need exists in managing negative and cognitive symptoms, which significantly impact long-term functioning.
• Treatment adherence remains a critical challenge, driving relapse rates and repeated hospitalizations.
• Increasing adoption of long-acting injectable antipsychotics (LAIs) to improve compliance and reduce disease burden.

Market Overview

• The Italy schizophrenia market is projected to grow from $304M to $335M, reflecting modest market expansion.
• Market growth is driven by:
• Increased uptake of long-acting injectable therapies
• Expansion of maintenance treatment strategies
• Despite stable patient population growth, market value is supported by chronic treatment duration and relapse prevention strategies.
• Continued innovation in novel antipsychotics and digital/behavioral interventions is expected to shape future market dynamics.
• Future growth will depend on therapies addressing negative symptoms, cognitive deficits, and adherence improvement.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• LB Pharmaceuticals Inc.
• Vanda Pharmaceuticals
• Novartis Pharmaceuticals
• AbbVie
• Eli Lilly and Company
• Otsuka Pharmaceutical Co., Ltd.
• Anavex Life Sciences Corp.
• Anxo Pharmaceutical Co., Ltd.
• Qilu Pharmaceutical Co., Ltd.
• Spinogenix
• MapLight Therapeutics
• Bristol-Myers Squibb
• Boryung Pharmaceutical Co., Ltd
• Click Therapeutics, Inc.
• Merck Sharp & Dohme LLC
• Hoffmann-La Roche
• Celon Pharma SA
• Boehringer Ingelheim
• ACADIA Pharmaceuticals Inc.
• Janssen-Cilag Ltd.
• Intra-Cellular Therapies, Inc.
• NeuShen Therapeutics
• Newron Pharmaceuticals SPA
• Alto Neuroscience
• Alkermes, Inc.